CoChat

TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer

Open access
Bardia, Aditya, Jhaveri, Komal, Kalinsky, Kevin, Pernas, Sonia, Tsurutani, Junji, Xu, Binghe, Hamilton, Erika, Im, Seock-Ah, Nowecki, Zbigniew, Sohn, Joohyuk, Laurentiis, Michelino De, Jañez, Noelia Martínez, Adamo, Barbara, Lee, Keun Seok, Jung, Kyung Hae, Rubovszky, Gábor, Tseng, Ling-Ming, Lu, Yen-Shen, Yuan, Yuan, Maxwell, Micah J, Haddad, Vincent, Khan, Sabrina S, Rugo, Hope S, Pistilli, Barbara · 2024 · Future Oncology
Cited by 72

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Improving the prognosis for patients with metastatic HR+/HER2- breast cancer remains an unmet need. Patients with tumors that have progressed on endocrine therapy and/or are not eligible for endocrine therapy had limited treatment options beyond chemotherapy. Antibody-drug conjugates are a novel and promising treatment class in this setting. Datopotamab deruxtecan (Dato-DXd) consists of a TROP2-directed humanized IgG1 monoclonal antibody attached via a serum-stable cleavable linker to a topoisomerase I inhibitor payload. TROPION-Breast01 is an ongoing phase 3 study that is evaluating the efficacy and safety of Dato-DXd compared with investigator's choice of standard-of-care chemotherapy in patients with inoperable or metastatic HR+/HER2- breast cancer who have received one or two prior lines of systemic chemotherapy in the inoperable or metastatic setting. Clinical Trial Registration: NCT05104866 (ClinicalTrials.gov)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2217/fon-2023-0188

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 72

Metadata

Authors
Bardia, A., Jhaveri, K., Kalinsky, K., Pernas, S., Tsurutani, J., Xu, B., Hamilton, E., Im, S.-A., Nowecki, Z., Sohn, J., Laurentiis, M. D., Jañez, N. M., Adamo, B., Lee, K. S., Jung, K. H., Rubovszky, G., Tseng, L.-M., Lu, Y.-S., Yuan, Y., Maxwell, M. J., Haddad, V., Khan, S. S., Rugo, H. S., & Pistilli, B.
Venue
Future Oncology
Published
2023-06-30
Volume
20
Issue
8
Pages
423-436
ISSN
  • 1479-6694 (ISSN-L)
  • 1744-8301
OpenAlex
W4382631498
Cited by
72
References
12
FWCI
11.44
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer. https://app.cochat.ai/papers/10.2217/fon-2023-0188
The paper
Bardia, A., Jhaveri, K., Kalinsky, K., Pernas, S., Tsurutani, J., Xu, B., Hamilton, E., Im, S.-A., Nowecki, Z., Sohn, J., Laurentiis, M. D., Jañez, N. M., Adamo, B., Lee, K. S., Jung, K. H., Rubovszky, G., Tseng, L.-M., Lu, Y.-S., Yuan, Y., . . . Pistilli, B. (2024). TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer. Future Oncology. https://doi.org/10.2217/fon-2023-0188

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.